Breast Carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
We have identified the TAF/FGF5/FGFR2/c-Src/HER2 axis as an escape pathway responsible for HER2 targeted therapies resistance in breast cancer which can be reversed by FGFR inhibitors.
|
31699826 |
2020 |
Breast Carcinoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Significant association with BC was confirmed in 2 SNPs: rs2981582 FGFR2 and rs889312 MAP3K1, and the odds ratios of homozygotes with two risk alleles in both SNP's were higher than in heterozygotes with one mutant allele, as follows: FGFR2 TT: 1.953 (95%CI 1.014-3.834, p = 0.049), CT 1.771 (95%CI 1.088-2.899, p = 0.026) and MAP3K1 CC 2.894 (95%CI 1.028-9.566, p = 0.048), AC 1.760 (95%CI 1.108-2.813, p = 0.019).
|
31002855 |
2019 |
Breast Carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
We found that NEF possessed the anti-growth and anti-metastasis effect on MDA-MB-231 cells through regulating miR-374a/FGFR-2, which might provide new insight for breast cancer management.
|
31207222 |
2019 |
Breast Carcinoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
AA genotype and A allele of P21 and TT genotypes and T allele of FGFR2 were significantly more frequent and were associated with an increased risk of early-onset of breast cancer (95%CI: 2.54 and 1.59; 2.63 and 1.64, respectively).
|
31759353 |
2019 |
Breast Carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
In addition, we illustrate how breast cancer pathway analysis can be confounded by the frequency of FGFR2 in pathway lists.
|
30875371 |
2019 |
Breast Carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
In this study we used FGFR1 and FGFR2 gene amplifications containing human MFM223 breast cancer cells in an experimental xenograft model of breast cancer bone growth using intratibial inoculation technique.
|
30956945 |
2019 |
Breast Carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
Moreover, signaling through FGFR2, a known risk factor in breast cancer development, augmented these interactions and further repressed ESR1 target gene expression.
|
29180470 |
2018 |
Breast Carcinoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
In tumor cell lines displaying molecular alterations in potential nintedanib targets, the inhibitor demonstrates direct antiproliferative effects: in the NSCLC cell line NCI-H1703 carrying a PDGFR<i>α</i> amplification (ampl.); the gastric cancer cell line KatoIII and the breast cancer cell line MFM223, both driven by a FGFR2 amplification; AN3CA (endometrial carcinoma) bearing a mutated FGFR2; the acute myeloid leukemia cell lines MOLM-13 and MV-4-11-B with FLT3 mutations; and the NSCLC adenocarcinoma LC-2/ad harboring a CCDC6-RET fusion.
|
29263244 |
2018 |
Breast Carcinoma
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
Depletion of CD151 in breast cancer cells resulted in an increased level of FGFR2.
|
30257985 |
2018 |
Breast Carcinoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
The association of the fibroblast growth factor receptor 2 gene (<i>FGFR2</i>) polymorphism rs2981582 with breast cancer has been extensively studied, whereas the role of this polymorphism in non-functioning pituitary adenoma (NFPA) has not been elucidated.
|
30206133 |
2018 |
Breast Carcinoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
The SNPs of FGFR2 rs1219648 and PI3KCA rs6443624 may contribute to the identification of breast cancer patients at risk of more aggressive disease and may be potential prognostic factors in breast cancer in a Chinese population.
|
29872343 |
2018 |
Breast Carcinoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
We have revealed significant association of FGFR2 and MAP3K1 polymorphisms with breast cancer.
|
29372690 |
2017 |
Breast Carcinoma
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
Fibroblast growth factor receptor 2 (FGFR2) is overexpressed in breast cancer tissues and cells, and has been shown to be a susceptibility factor for breast cancer.
|
28132898 |
2017 |
Breast Carcinoma
|
0.500 |
GeneticVariation
|
disease |
GWASCAT |
Association analysis identifies 65 new breast cancer risk loci.
|
29059683 |
2017 |
Breast Carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
Fibroblast Growth Factor Receptor 2 Signaling in Breast Cancer.
|
29104507 |
2017 |
Breast Carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
(FGFR2) on genetic susceptibility for breast cancer.(BC) in Chinese populations.
|
27461607 |
2017 |
Breast Carcinoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
BC patients (n = 1687) randomly sampled in an adjuvant, randomized phase III trial (SUCCESS A study) were genotyped for nine BC risk SNPs: rs17468277 <i>(CASP8)</i> , rs2981582 <i>(FGFR2)</i> , rs13281615(8q24), rs3817198 <i>(LSP1)</i> , rs889312 <i>(MAP3K1)</i> , rs3803662 <i>(TOX3)</i> , rs13387042(2q35), rs4973768 <i>(SLC4A7)</i> , rs6504950 <i>(COX11)</i> .
|
28757652 |
2017 |
Breast Carcinoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
This meta-analysis of case-control studies provides strong evidence that fibroblast growth factor 2 (FGFR2; rs11200014, rs2981579, and rs1219648) polymorphisms are significantly associated with the BC risk.
|
29390357 |
2017 |
Breast Carcinoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
The purpose of this systematic review was to evaluate the relationship between FGFR2 (rs2981582, rs2420946 and rs2981578) polymorphism and BC risk.
|
27966449 |
2017 |
Breast Carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
These results unveil the complexity of ER regulation by FGFR2-mediated signaling likely to be associated with BCa resistance to endocrine therapy.
|
28869838 |
2017 |
Breast Carcinoma
|
0.500 |
GeneticVariation
|
disease |
GWASCAT |
Genome-wide association study in East Asians identifies two novel breast cancer susceptibility loci.
|
27354352 |
2016 |
Breast Carcinoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
The FGFR2 locus is known to be associated with breast cancer risk.
|
27764800 |
2016 |
Breast Carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
The FGFR2 gene was associated with risk of overall breast cancer (P = 0.002) and ER-positive breast cancer (P = 0.002).
|
26743380 |
2016 |
Breast Carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
Herein, we have undertaken an evaluation of a possible relationship between FGFR2/RSK2 interdependence and disease outcome in breast cancer (BCa) patients.
|
27476168 |
2016 |
Breast Carcinoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Fifty-three studies with a total of 121,740 cases and 198,549 controls have examined the associations between 23 variants in intron 2 of FGFR2 and the breast cancer risk.
|
26728143 |
2016 |